Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Elizabeth M. Coyle"'
Autor:
Youri Lee, Laura Klenow, Elizabeth M. Coyle, Gabrielle Grubbs, Hana Golding, Surender Khurana
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Currently, only Palivizumab and Nirsevimab that target the respiratory syncytical virus (RSV) fusion protein are licensed for pre-treatment of infants. Glycoprotein-targeting antibodies may also provide protection against RSV. In this study,
Externí odkaz:
https://doaj.org/article/b2e10af17bb8459ea84238f56db68125
Autor:
Juanjie Tang, Supriya Ravichandran, Youri Lee, Gabrielle Grubbs, Elizabeth M. Coyle, Laura Klenow, Hollie Genser, Hana Golding, Surender Khurana
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
SARS-CoV2 infection has been linked to a wide range of clinical severities and the immunopathology is still under intense scrutiny. Here, the authors uncover an association of antibody affinity maturation and plasma IgA levels with clinical outcome i
Externí odkaz:
https://doaj.org/article/31cff301b7dd4bd78c29bf2e37eef897
Autor:
Surender Khurana, Megan Hahn, Elizabeth M. Coyle, Lisa R. King, Tsai-Lien Lin, John Treanor, Andrea Sant, Hana Golding
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Here, Khurana et al. report the results of a phase 4 clinical trial with three FDA approved influenza vaccines and show that repeat influenza vaccination results in reduced antibody affinity maturation to hemagglutinin domain 1 irrespective of vaccin
Externí odkaz:
https://doaj.org/article/25c5be5b8b3340e9bfab6fabc559795c
Publikováno v:
iScience, Vol 23, Iss 3, Pp - (2020)
Summary: Limited knowledge exists on the quality of polyclonal antibody response generated following Ebola virus (EBOV) infection compared with vaccination. Polyclonal antibody repertoire in plasma following EBOV infection in survivors was compared w
Externí odkaz:
https://doaj.org/article/da4edc9e21a942c1a093360a5cfb59ec
Publikováno v:
PLoS Pathogens, Vol 14, Iss 8, p e1007262 (2018)
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract disease in infants. Previously, we elucidated the antibody repertoire following primary RSV infection in infants. Whole genome-fragment phage display libraries (GFPDL) ex
Externí odkaz:
https://doaj.org/article/c35f07fde30641cc84d982b392420317
Publikováno v:
PLoS Pathogens, Vol 12, Iss 4, p e1005554 (2016)
Respiratory Syncytial Virus (RSV) is the major cause of pneumonia among infants. Here we elucidated the antibody repertoire following primary RSV infection and traced its evolution through adolescence and adulthood. Whole genome-fragment phage displa
Externí odkaz:
https://doaj.org/article/2efd1dfb994543d289ff2cdaf4480072
Autor:
J. Brian Kimble, Meghan Wymore Brand, Bryan S. Kaplan, Phillip Gauger, Elizabeth M. Coyle, Katarina Chilcote, Surender Khurana, Amy L. Vincent
Publikováno v:
J Virol
Influenza A virus (IAV) causes respiratory disease in swine and humans. Vaccines are used to prevent influenza illness in both populations but must be frequently updated due to rapidly evolving strains. Mismatch between the circulating strains and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fe851f8a81d564ca07ed51ff2e3ee6d
https://pubmed.ncbi.nlm.nih.gov/34985999
https://pubmed.ncbi.nlm.nih.gov/34985999
Autor:
Laura Klenow, Juanjie Tang, Youri Lee, Surender Khurana, Hana Golding, Supriya Ravichandran, Elizabeth M. Coyle, Jeehyun Lee
Publikováno v:
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 14, Iss 1, Pp n/a-n/a (2022)
EMBO Molecular Medicine, Vol 14, Iss 1, Pp n/a-n/a (2022)
Respiratory syncytial virus (RSV) vaccines primarily focused on surface fusion (F) protein are under development. Therefore, to identify RSV‐F protective epitopes, we evaluated 14 antigenic sites recognized following primary human RSV infection. BA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7ce34f13c0f421cc8c656797eeb8569
http://europepmc.org/articles/PMC8749483
http://europepmc.org/articles/PMC8749483
Autor:
Surender Khurana, Elizabeth M Coyle, Jody Manischewitz, Lisa R King, Glenn Ishioka, Jeff Alexander, Jon Smith, Marc Gurwith, Hana Golding
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0115476 (2015)
A Phase I trial conducted in 2009-2010 demonstrated that oral vaccination with a replication competent Ad4-H5 (A/Vietnam) vector with dosages ranging from 107-1011 viral particles was well tolerated. HA-specific T-cell responses were efficiently indu
Externí odkaz:
https://doaj.org/article/2f4a91ee8c2445f793525c6fccdf81f6
Autor:
Jeehyun Lee, Andrew B. Ward, Juanjie Tang, Laura Klenow, Kazuyo Takeda, Surender Khurana, Hannah L. Turner, Elizabeth M. Coyle, Hana Golding, Jody Manischewitz, Katie L. Winarski
Publikováno v:
Proceedings of the National Academy of Sciences. 116:15194-15199
Several next-generation (universal) influenza vaccines and broadly neutralizing antibodies (bNAbs) are in clinical development. Some of these mediate inhibitions of virus replication at the postentry stage or use Fc-dependent mechanisms. Nonneutraliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dba2c77e2f4519ac66d7430b9d76b729
https://doi.org/10.1073/pnas.1821317116
https://doi.org/10.1073/pnas.1821317116